Jefferies initiated coverage on Adicet Bio with a new price target
$ACET
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies initiated coverage of Adicet Bio with a rating of Buy and set a new price target of $27.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/30/2024 | $7.00 | Buy | Guggenheim |
| 9/11/2024 | Buy → Neutral | H.C. Wainwright | |
| 6/27/2023 | Buy → Neutral | Guggenheim | |
| 6/27/2023 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 6/1/2023 | $20.00 → $6.00 | Overweight → Neutral | JP Morgan |
| 9/21/2022 | $23.00 | Overweight | JP Morgan |
| 3/31/2022 | $28.00 | Outperform | SMBC Nikko |
| 3/8/2022 | $30.00 | Buy | Truist Securities |
4 - Adicet Bio, Inc. (0001720580) (Issuer)
4 - Adicet Bio, Inc. (0001720580) (Issuer)
4 - Adicet Bio, Inc. (0001720580) (Issuer)
4 - Adicet Bio, Inc. (0001720580) (Issuer)
4 - Adicet Bio, Inc. (0001720580) (Issuer)
4 - Adicet Bio, Inc. (0001720580) (Issuer)
SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)
SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)
SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)
Guggenheim resumed coverage of Adicet Bio with a rating of Buy and set a new price target of $7.00
H.C. Wainwright downgraded Adicet Bio from Buy to Neutral
Guggenheim downgraded Adicet Bio from Buy to Neutral
Expanding clinical development of ADI-001 into autoimmune diseases following clearance of Investigational New Drug Application (IND); plan to initiate Phase 1 clinical study in 2Q 2024 Focusing enrollment on mantle cell lymphoma (MCL) in ongoing ADI-001 Phase 1 clinical trial given favorable complete response (CR) rate, durability, and safety ADI-001 clinical update expected 2H 2024 ADI-270 IND submission in renal cell carcinoma expected in 2Q 2024 Updated cash runway into 2H 2025 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, today provided corporate upda
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that the Company will host a conference call and webcast presentation on Thursday, January 4, 2024 at 8:00am ET to provide an update on its clinical pipeline and corporate outlook. Conference Call and Webcast Event The live webcast of the presentation can be accessed by registering under "Presentations & Events" in the investors section of the Company's website at https://www.adicetbio.com. Upon registration, all participants will receive a confirmation email with a unique passcode to provide access to the webcast event. To
ADI-001 demonstrated 71% overall response rate (ORR) and 63% complete response (CR) rate across all dose levels in patients with median 4 prior lines of therapy; 50% of patients enrolled had previously progressed on anti-CD19 chimeric antigen receptor T cell (CAR T) therapy 83% ORR and 67% CR rate observed in heavily pre-treated patients who had progressed on prior CAR T Six-month CR rate consistent with autologous CAR T cell therapy Favorable safety with no significant incidence of CRS (cytokine release syndrome) or ICANS (immune effector cell associated neurotoxicity syndrome) Robust pharmacokinetic profile in dose level 4 (DL4) with Cmax and Day 28 persistence exceeding approved
First gamma delta CAR T cell therapy with the potential to address solid tumors entering clinical trials Preliminary Phase 1 clinical data expected in the first half of 2025 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC). "Solid tumors represent one of the highest unmet medical needs in oncology and have yet to benefit from the breakthroughs observed with CAR T cell therapies in hematologic mal
Enrollment underway for lupus nephritis (LN) patients Preliminary clinical data in LN anticipated in 1H25 Initiation of patient enrollment in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS) expected in 1Q25; patient enrollment in anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV) expected in 2H25 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first LN patient has been dosed in the Phase 1 clinical trial evaluating ADI-001 in au
ADI-001 Phase 1 clinical trial expanded to include a total of six autoimmune disease indications; preliminary clinical data in lupus nephritis (LN) anticipated in 1H25 Strong balance sheet with $202.1 million in cash, cash equivalents and short-term investments as of September 30, 2024 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2024. "Our commitment to delivering best-in-class gamma delta 1 T cell therapies for patients battling autoimmune diseases and cancer
HC Wainwright & Co. analyst Edward White reiterates Adicet Bio (NASDAQ:ACET) with a Buy and maintains $10 price target.
8-K - Adicet Bio, Inc. (0001720580) (Filer)
8-K - Adicet Bio, Inc. (0001720580) (Filer)
10-Q - Adicet Bio, Inc. (0001720580) (Filer)
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Lloyd Klickstein, M.D., Ph.D. to its Board of Directors. "We are pleased to welcome Dr. Klickstein to our Board of Directors," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "Dr. Klickstein's expertise in rheumatology and immunology, proven track record in drug development and his scientific knowledge of our gamma delta T cell platform as a former executive at Adicet will be very valuable as we progress our autoimmune programs across multiple indications. I loo
Announced encouraging safety and efficacy data in ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) On track to report a clinical update for ADI-001 in second half of 2024 Plan to file Investigational New Drug Application (IND) for ADI-925 in H2 2023 and ADI-270 in H1 2024 Strong balance sheet with $205.5 million in cash and cash equivalents as of June 30, 2023 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2023.
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the appointment of Katie Peng to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230711946213/en/Katie Peng, Board of Directors, Adicet Bio, Inc. (Photo: Business Wire) "We are delighted to welcome Katie to our Board of Directors," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "Her proven success as a commercial leader in both the U.S. and globally will be particularly valuable to Adicet as we advance ADI-001 and our pi